세계의 항부정맥제 시장 - 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Beta Blockers, Sodium Channel Blockers), By Route of Administration (Oral, Parenteral), By Distribution Channel, By Region, and Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

항부정맥제 시장의 성장과 동향

세계의 항부정맥제 시장 규모는 2030년에 16억 달러에 달할 것으로 예측되며, 2025-2030년 동안 CAGR 6.35%로 성장할 것으로 예측됩니다. 이러한 예측성장은 심혈관질환(CVDs)의 유병률 상승, 세계 인구의 고령화, 의약품 개발의 진보, 규제 당국의 지원, 심혈관 건강 개선을 목적으로 하는 정부의 대처 등, 상호 관련된 여러 요인에 의해 초래됩니다. 세계보건기구(WHO)에 따르면 CVD는 세계 사망 원인 1위이며 연간 약 1,790만 명이 사망하고 있습니다.

게다가 고령화도 시장 확대의 큰 요인이 되고 있습니다. 미국 인구조사국에 따르면 2030년까지 미국 인구의 약 20%가 65세 이상이 될 것으로 보고되었습니다. 이 인구 역학의 변화는 부정맥을 포함한 심혈관계 질환을 증가시키고 항부정맥제에 대한 수요를 높일 것으로 예상됩니다. 나이가 들어감에 따라 심장 질환의 개발 위험이 증가하고 지속적인 치료 및 관리 전략이 필요합니다. 이 동향은 미국에 한정되지 않고, 많은 선진국이나 개발도상국에서도 비슷한 인구동태의 변화가 발생하고 있어, 그 결과 항부정맥제에 대한 수요가 세계적으로 높아지고 있습니다.

최근 약물 개발 동향은 시장 성장을 더욱 강화하고 있습니다. 항부정맥제 부문의 연구와 혁신은 새로운 화합물과 치료 접근법의 도입으로 이어졌습니다. 예를 들어, 특정 이온 채널을 표적으로 하는 신약 제제의 개발은 이러한 약제의 효능 및 안전성 프로파일을 개선합니다. 게다가, 개인화된 의료 및 약리 유전체학의 진보는 개별 환자프로파일에 기초하여 약효를 최적화하는 맞춤형 치료 전략에 대한 길을 열고 있습니다. 이러한 기술 혁신은 치료 성적을 향상시킬 뿐만 아니라 의료 종사자의 항부정맥 요법의 채용을 촉진하고 있습니다.

항 부정맥 약물 시장 보고서 하이라이트

• 약물 종류별로는 베타 차단제가 2024년에 34.80%의 최대 판매 점유율을 차지했습니다. 심박수의 저하나 혈압의 컨트롤에 유효하기 때문에 이러한 질환의 치료의 요점이 되고 있습니다.
• 투여 경로별로는 경구제가 2024년에 약 71.0%로 최대의 매출 점유율을 차지했습니다. 경구 제형은 환자가 집에서 치료를 자가 관리할 수 있기 때문에 침습적인 치료 및 통원의 필요성이 없으며 심방 세동 및 심실 빈맥과 같은 만성 질환의 관리에 특히 매력적입니다.
• 유통 채널별로는 2024년 항부정맥제 세계 시장에서 병원 약국 부문이 약 60.53%의 최대 판매 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항부정맥제 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 항부정맥제 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 항부정맥제 시장 : 약물 종류별, 추정·동향 분석

• 항부정맥제 시장 : 약물 종류 대시보드
• 항부정맥제 시장 : 약물 종류의 변동 분석
• 항부정맥제 시장 : 약물 종류별, 수익별
• 나트륨 채널 차단제
• 칼륨 채널 차단제
• 칼슘 채널 차단제
• 기타

제5장 항부정맥제 시장 : 투여 경로별, 추정·동향 분석

• 항부정맥제 시장 : 투여 경로 대시보드
• 항부정맥제 시장 : 투여 경로의 변동 분석
• 투여 경로별 수익
• 경구
• 비경구
• 기타

제6장 항부정맥제 시장 : 유통 채널별, 추정·동향 분석

• 항부정맥제 시장 : 유통 채널 대시보드
• 유통 채널별, 수익
• 병원 약국
• 소매 약국
• 기타

제7장 항부정맥제 시장 : 약제 종류에 의한 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁의 분류
• 벤더 상황
  • 주요 리셀러와 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석, 2024년
  • Pfizer
  • Novartis
  • Mylan
  • Baxter International
  • Sanofi
  • GlaxoSmithKline
  • Mayne Pharma
  • Upsher-Smith Laboratories
  • Amomed Pharma
  • Merck

JHS

영문 목차

영문목차

Antiarrhythmic Drugs Market Growth & Trends:

The global antiarrhythmic drugs market size is expected to reach USD 1.6 billion in 2030 and is projected to grow at a CAGR of 6.35% from 2025 to 2030. This anticipated growth is driven by multiple interrelated factors, including the rising prevalence of cardiovascular diseases (CVDs), an aging global population, advancements in drug development, regulatory support, and government initiatives aimed at improving cardiovascular health. According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for approximately 17.9 million deaths annually.

Furthermore, the aging population is a significant factor contributing to market expansion. The U.S. Census Bureau reports that by 2030, approximately 20% of the U.S. population will be 65 years or older. This demographic shift is expected to lead to an increase in cardiovascular conditions, including arrhythmias, thereby heightening the demand for antiarrhythmic drugs. As people age, their risk of developing heart conditions increases, necessitating ongoing treatment and management strategies. This trend is not limited to the U.S.; many developed and developing nations are experiencing similar demographic changes, resulting in a global increase in demand for antiarrhythmic therapies.

Recent advancements in drug development are further propelling market growth. Research and innovation in the field of antiarrhythmic drugs have led to the introduction of novel compounds and therapeutic approaches. For instance, the development of new drug formulations that target specific ion channels has improved the efficacy and safety profiles of these medications. Moreover, advances in personalized medicine and pharmacogenomics are paving the way for tailored treatment strategies that optimize drug efficacy based on individual patient profiles. Such innovations not only enhance treatment outcomes but also encourage the adoption of antiarrhythmic therapies among healthcare providers.

Antiarrhythmic Drugs Market Report Highlights:

• By drug class, the beta blockers segment accounted for the largest revenue share of 34.80% in 2024. Their efficacy in reducing heart rate and controlling blood pressure has made them a cornerstone in the treatment of these disorders.
• Based on route of administration, the oral segment accounted for the largest revenue share of around 71.0% in 2024. Oral formulations allow patients to self-administer treatments at home, eliminating the need for invasive procedures or hospital visits, which can be particularly appealing in managing chronic conditions such as atrial fibrillation and ventricular tachycardia.
• Based on distribution channels, the hospital pharmacies segment accounted for the largest revenue share of around 60.53% in global market for antiarrhythmic drugs in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antiarrhythmic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
    • 3.2.1.2. Advancements in Drug Development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Drug Class Cost
    • 3.2.2.2. Competition from Alternative Therapies
• 3.3. Antiarrhythmic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antiarrhythmic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Antiarrhythmic Drugs Market: Drug Class Dashboard
• 4.2. Antiarrhythmic Drugs Market: Drug Class Movement Analysis
• 4.3. Antiarrhythmic Drugs Market by Drug Class, Revenue
• 4.4. Sodium Channel Blockers
  • 4.4.1. Sodium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Potassium Channel Blockers
  • 4.5.1. Potassium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Calcium Channel Blockers
  • 4.6.1. Calcium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antiarrhythmic Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. Antiarrhythmic Drugs Market: Route of Administration Dashboard
• 5.2. Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
• 5.3. Antiarrhythmic Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Oral
  • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Parenteral
  • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antiarrhythmic Drugs Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Antiarrhythmic Drugs Market: Distribution Channel Dashboard
• 6.2. Antiarrhythmic Drugs Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Other
  • 6.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antiarrhythmic Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Route of Administration, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key company market share analysis, 2024
  • 8.2.3. Pfizer
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Novartis
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Mylan
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Baxter International
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Sanofi
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. GlaxoSmithKline
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Mayne Pharma
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Upsher-Smith Laboratories
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Amomed Pharma
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. Merck
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives

관련자료